GleamWall
中文EN

SCNI Scinai Immunotherapeutics Ltd.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1611747 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY99.2%
TTM net income YoY-273.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-202.3%
Operating margin-575.3%
Net margin-633.6%
FCF margin-461.9%
EBITDA margin-466.9%

Returns

ROE-91.9%
ROA-66.3%
ROIC (approx.)-82.4%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets30.3%
Debt / equity0.00x
Current ratio1.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2023Q22023-06-30 · USD2023Q12023-03-31 · USD2022Q22022-06-30 · USD2022Q12022-03-31 · USD2021Q3*2021-09-30 · ILS2021Q2*2021-06-30 · ILS2020Q4*2020-12-31 · ILS2020Q3*2020-09-30 · ILS
Income statement
Revenue————————
R&D expense$1.45M$2.00M$1.97M$1.16M2.02M1.90M7.87M12.58M
SG&A expense$1.14M$1.19M$1.29M$1.45M6.20M7.00M4.26M7.30M
Operating income-$2.60M-$3.19M-$3.26M-$2.62M————
Interest expense——3.64MILS—2.80M3.09M773,000288,000
Net income-$3.76M-$3.52M-$2.98M-$2.48M-9.05M-11.99M-14.10M55.31M
EBITDA-$2.45M-$3.05M-$3.12M-$2.48M————
EPS (basic)-0.00-0.00-0.00-0.00-0.02-0.03—0.12
EPS (diluted)-0.00-0.00-0.00-0.00-0.02-0.03—0.10
Weighted avg. shares (diluted)1.35B1.30B746.90M744.71M573.21M573.21M—538.50M
Balance sheet
Cash & equivalents$7.51M$10.80M$11.29M$15.39M34.67M39.88M9.42M24.77M
Receivables——$179,000—1.43M2.64M1.20M2.93M
Current assets$7.77M$11.04M$11.46M—36.10M42.52M10.62M27.70M
PP&E, net$10.80M$10.82M$11.21M—38.61M38.98M39.61M39.89M
Total assets$19.90M$23.29M$24.45M—81.03M88.05M56.91M74.92M
Current liabilities$1.89M$2.58M$6.72M—70.27M69.39M64.19M11.15M
Total liabilities$27.01M$28.10M$23.17M—76.84M76.66M71.51M76.76M
Shareholders' equity-$7.11M-$4.81M$3.26M-$862,0004.19M11.39M-14.60M-1.84M
Shares outstanding1.45B1.31B——————
Cash flow statement
Operating cash flow-$2.88M-$3.06M-10.41MILS-$1.10M-6.19M-7.91M-15.91M-10.31M
Capital expenditure$377,000$6,00044,000ILS$521,0004,000106,00097,0003.35M
Free cash flow-$3.25M-$3.06M-10.45MILS-$1.63M-6.19M-8.02M-16.00M-13.66M
Investing cash flow-$377,000-$6,000-84,000ILS-$521,000-13,000-107,000321,000-3.35M
Financing cash flow——-468,000ILS—-988,000-317,000-312,000-140,000
Depreciation & amortization$147,000$138,000$145,000$134,000————
Stock-based compensation$200,000$252,0001.30MILS$485,0002.53M2.58M1.34M4.60M

Free plan shows the latest 8 periods; Pro shows all 12 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.